We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Randomised Study Comparing Three Chemotherapy Regimens in Non-small Cell Lung Cancer

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00622349
First Posted: February 25, 2008
Last Update Posted: January 30, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
European Lung Cancer Working Party
February 14, 2008
February 25, 2008
January 30, 2013
February 2004
March 2009   (Final data collection date for primary outcome measure)
Survival [ Time Frame: Survival will be dated from the first day of registration until death or last follow up ]
Same as current
Complete list of historical versions of study NCT00622349 on ClinicalTrials.gov Archive Site
  • Response rate [ Time Frame: Every 3 courses of chemotherapy ]
  • Toxicity [ Time Frame: After each course of chemotherapy ]
  • Activity of second-line chemotherapy [ Time Frame: Every 3 courses of chemotherapy ]
Same as current
Not Provided
Not Provided
 
Randomised Study Comparing Three Chemotherapy Regimens in Non-small Cell Lung Cancer
A Phase III Randomised Study Comparing Three Combination Chemotherapy Regimens in Patients With Non Pre-treated Advanced Non-small Cell Lung Cancer
The purpose of this study is to determine if cisplatin-based chemotherapy, cisplatin-gemcitabine-ifosfamide or cisplatin-docetaxel, will improve survival in comparison to the combination gemcitabine-ifosfamide in patients with advanced NSCLC
Not Provided
Interventional
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Carcinoma, Non-Small-Cell Lung
  • Drug: Cisplatin, Ifosfamide, Gemcitabine
    Cisplatin 50 mg/m² day 1 Ifosfamide 3g/m² day 1 (+ uromitexan rescue) Gemcitabine 1 g/m² days 1 and 8 Cycles every 3 weeks
  • Drug: Ifosfamide, Gemcitabine
    Ifosfamide 3g/m² day 1 (+ uromitexan rescue) Gemcitabine 1 g/m² days 1 and 8 Cycles every 3 weeks
  • Drug: Cisplatin, docetaxel
    Cisplatin 50 mg/m² day 1 Docetaxel 75 mg/m² day 1 Cycles every 3 weeks
  • Experimental: A
    Intervention: Drug: Cisplatin, Ifosfamide, Gemcitabine
  • Active Comparator: B
    Intervention: Drug: Ifosfamide, Gemcitabine
  • Experimental: C
    Intervention: Drug: Cisplatin, docetaxel
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
707
December 2009
March 2009   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Histological or cytological diagnosis of non-small cell lung cancer
  • Advanced (unresectable or functionally inoperable) stage III or stage IV disease
  • Availability for participating in the detailed follow-up of the protocol
  • Presence of an evaluable or measurable lesion
  • Informed consent

Exclusion Criteria:

  • Prior treatment with chemotherapy
  • Operable patient with resectable tumour
  • Performance status < 60 on the Karnofsky scale
  • A history of prior malignant tumour, except non-melanoma skin cancer or in situ carcinoma of the cervix and cured malignant tumour (more than 5-year disease free interval)
  • Polynuclear cells < 2,000/mm³
  • Platelet cells < 100,000/mm³
  • Serum bilirubin >1.5 mg/100 ml
  • Serum creatinine > 1.5 mg/100 ml and/or creatinine clearance < 60 ml/min
  • Perception hypoacousia
  • Peripheral neuropathy
  • Recent myocardial infarction (less than 3 months prior to date of diagnosis)
  • Congestive cardiac failure requiring medical therapy or uncontrolled cardiac arrhythmia
  • Uncontrolled infectious disease
  • Serious medical or psychological factors which may prevent adherence to the treatment schedule
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Belgium,   France,   Greece,   Spain
 
 
NCT00622349
ELCWP-01041
Yes
Not Provided
Not Provided
European Lung Cancer Working Party
European Lung Cancer Working Party
Not Provided
Study Chair: Jean-Paul Sculier, MD, PhD European Lung Cancer Working Party
European Lung Cancer Working Party
January 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP